BridgeBio Pharma Cash Flow from Operating Activities 2018-2026 | BBIO
BridgeBio Pharma annual/quarterly cash flow from operating activities history and growth rate from 2018 to 2026. Cash flow from operating activities can be defined as a company's cash flows from operations.
- BridgeBio Pharma cash flow from operating activities for the quarter ending March 31, 2026 was $-0.197B, a 0.98% decline year-over-year.
- BridgeBio Pharma cash flow from operating activities for the twelve months ending March 31, 2026 was $-1.313B, a 10.28% increase year-over-year.
- BridgeBio Pharma annual cash flow from operating activities for 2025 was $-0.446B, a 14.37% decline from 2024.
- BridgeBio Pharma annual cash flow from operating activities for 2024 was $-0.521B, a 1.33% decline from 2023.
- BridgeBio Pharma annual cash flow from operating activities for 2023 was $-0.528B, a 25.8% increase from 2022.
|
BridgeBio Pharma Annual Cash Flow Ops (Millions of US $) |
|
|---|---|
| 2025 | $-446 |
| 2024 | $-521 |
| 2023 | $-528 |
| 2022 | $-419 |
| 2021 | $-498 |
| 2020 | $-400 |
| 2019 | $-254 |
| 2018 | $-137 |
| 2017 | $-40 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |